<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01759797</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-Nerve-005</org_study_id>
    <nct_id>NCT01759797</nct_id>
  </id_info>
  <brief_title>Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS</brief_title>
  <official_title>Safety of Intravenous Transplantation of Bone Marrow Derived Mesenchymal Stem Cell in Patients With ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ALS is a debilitating disease with varied etiology characterized by rapidly progressive
      weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking
      (dysarthria), difficulty swallowing (dysphagia), and difficulty breathing (dyspnea). ALS is
      the most common of the five motor neuron diseases.Riluzole (Rilutek) is the only treatment
      that has been found to improve survival but only to a modest extent. It lengthens survival by
      several months, and may have a greater survival benefit for those with a bulbar onset. It
      also extends the time before a person needs ventilation support.Stem cell transplantation is
      a new hopeful way to improve the patients conditions and reduce the period of disabilities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study our purpose is to evaluate the safety of intraventricular injection of bone
      marrow derived mesenchymal stem cell.the patients who are eligible,underwent bone marrow
      aspiration.after cell separation and preparation,the patients underwent mesenchymal stem cell
      intraventricular injection by stereotaxis.after injection he will be under observed in ICU to
      monitor the adverse events(allergic and neurological side effects).patients are followed
      1th,3th ,6th and 12 months after injection and each time these parameters are
      checked:ALS-FRS,EMG-NCV,FVC,side effect check list.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fever</measure>
    <time_frame>48hours</time_frame>
    <description>Evaluation the rate of fever 48 hours after cell transplantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unconsciousness</measure>
    <time_frame>48hours</time_frame>
    <description>Evaluation the rate of unconsciousness 48hours after cell transplantation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>vomiting</measure>
    <time_frame>48hours</time_frame>
    <description>Evaluation the rate of vomiting 48hours after cell transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALS-FRS</measure>
    <time_frame>6months</time_frame>
    <description>Evaluation the improvement of ALS-FRS during 6months after cell transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC</measure>
    <time_frame>6months</time_frame>
    <description>Evaluation the improvement of FVC (spectrometry )in patients after cell transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EMG-NCV</measure>
    <time_frame>6months</time_frame>
    <description>Evaluation the improvement of EMG-NCV during 6 months after cell transplantation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>stem cell reciepient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the patients with ALS who underwent intravenous injection of mesenchymal stem cell.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>intra venous injection of stem cell</intervention_name>
    <description>Intra venous injection of mesenchymal stem cell</description>
    <arm_group_label>stem cell reciepient</arm_group_label>
    <other_name>Stem cell transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Age:18-65

          -  both gender

          -  duration of disease&lt;2 years

          -  FVC&gt;40% ALS-FRS&gt;26

        Exclusion Criteria:

          -  - neurological and psychiatric concomitant disease

          -  concomitant systemic disease

          -  treatment with corticosteroid,Ig,immunosuppressive during 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Head of Royan department of degenerative medicine,Head of Royan celltherapy center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seyed Masoud Nabavi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Proffessor assistant of Shahed University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://Royaninstitute.org</url>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2012</study_first_submitted>
  <study_first_submitted_qc>January 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2013</study_first_posted>
  <last_update_submitted>July 2, 2016</last_update_submitted>
  <last_update_submitted_qc>July 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS bone marrow mesenchymal stem cell intravenous injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

